

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RainMed
Rainmed Medical Limited
潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2297)

**PROPOSED ADOPTION OF THE FOURTH AMENDED AND
RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is made by Rainmed Medical Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) proposes to amend the third amended and restated memorandum and articles of association of the Company (the “**Existing M&A**”) to (i) bring its Existing M&A in line with the latest regulatory requirements in relation to the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules which took effect from 31 December 2023; and (ii) make certain other housekeeping amendments (collectively, the “**Proposed Amendments**”). In view of the Proposed Amendments, the Board proposes to adopt the fourth amended and restated memorandum and articles of association of the Company (the “**Fourth Amended and Restated M&A**”) in substitution for and to the exclusion of the Existing M&A.

The proposed adoption of the Fourth Amended and Restated M&A is subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting of the Company (the “**AGM**”), and will become effective upon the approval by the Shareholders at the AGM.

A circular containing, among other things, details of the proposed adoption of the Fourth Amended and Restated M&A, together with a notice convening the AGM will be despatched to the Shareholders in due course. As no Shareholder has a material interest in the proposed adoption of the Fourth Amended and Restated M&A, no Shareholder is required to abstain from voting on the resolutions proposed to consider and approve the proposed adoption of the Fourth Amended and Restated M&A.

The Company will make further announcement(s) to inform the Shareholders of the results of the AGM and the effective date of the proposed adoption of the Fourth Amended and Restated M&A as and when appropriate.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, April 24, 2024

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui, Mr. Zhang Liang and Ms. Gu Yang as executive directors, Mr. Wang Lin and Mr. Heng Lei as non-executive directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng as independent non-executive directors.